Vertex Pharmaceuticals (NASDAQ:VRTX) Posts Quarterly Earnings Results, Misses Estimates By $0.45 EPS

Vertex Pharmaceuticals (NASDAQ:VRTX) posted its quarterly earnings data on Monday. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45), Zacks reports. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. Vertex Pharmaceuticals updated its FY 2025 guidance to EPS.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $469.97 on Tuesday. The firm’s 50-day simple moving average is $435.87 and its 200 day simple moving average is $462.29. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a 12-month low of $377.85 and a 12-month high of $519.88.

Wall Street Analyst Weigh In

A number of analysts have commented on VRTX shares. BMO Capital Markets reduced their price objective on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating for the company in a research note on Friday, December 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $480.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Piper Sandler reduced their price target on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Stifel Nicolaus increased their price objective on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a report on Monday, December 16th. Finally, HC Wainwright boosted their price objective on shares of Vertex Pharmaceuticals from $535.00 to $550.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $502.58.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.